Therapeutic potential of amniotic-fluid-derived stem cells on liver fibrosis model in mice
Journal
Taiwanese Journal of Obstetrics and Gynecology
Journal Volume
53
Journal Issue
2
Pages
151-157
Date Issued
2014
Author(s)
Peng, S.-Y.
Chou, C.-J.
Cheng, P.-J.
Ko, I.-C.
Kao, Y.-J.
Chen, Y.-H.
Cheng, W.T.K.
Shaw, S.W.S.
Abstract
Objective: Liver fibrosis results from the wound healing response to chronic liver damage. Advanced liver fibrosis results in cirrhosis and liver failure, and liver transplantation is often the only option for effective therapy; however, the shortage of available donor livers limits this treatment. Thus, new therapies for advanced liver fibrosis are essential. Materials and methods: Amniotic fluid contains an abundance of stem cells, which are derived from all three germ layers of the developing fetus. These cells do not induce teratomas invivo and do not pose any ethical concerns. To generate liver fibrosis models, male ICR mice were treated with CCl4 via oral gavage for 4 weeks, and the serum levels of glutamate oxaloacetate transaminase, glutamate pyruvate transaminase, and albumin were higher than in the control group following chemical induction. To assess the potential of amniotic-fluid-derived stem cells (mAFSCs) to ameliorate liver fibrosis invivo, mAFSCs were isolated from amniotic fluid of 13.5-day-old transgenic mice, which globally express the fluorescent protein, enhanced green fluorescent protein (EGFP), for tracing purposes (EGFP-mAFSCs). Single cells were injected via the mesentery (1×106 cells/mouse) of transplanted mice with liver fibrosis. Results: Four weeks after EGFP-mAFSC transplantation, the serum glutamate oxaloacetate transaminase, glutamate pyruvate transaminase, and albumin levels of recipient mice in the EGFP-mAFSC-injected group were significantly decreased when compared with mice in the saline-injected group. Additionally, fibrotic tissues were evaluated using Masson's trichrome staining 4 weeks after cell transplantation. Shrinkage of the fibrotic area was observed in the EGFP-mAFSC-injected group. The tissue-repair effects were also confirmed by hydroxyproline content analysis. Conclusion: The possible repair mechanism from our data revealed that EGFP-mAFSCs may fuse with the recipient liver cells. Overall, EGFP-mAFSCs can ameliorate liver fibrosis in mice, thus providing insight into the future development of regenerative medicine. ? 2014.
Subjects
Amniotic-fluid-derived stem cells; Liver fibrosis; Mice; Transplantation
SDGs
Other Subjects
alanine aminotransferase; albumin; aspartate aminotransferase; carbon tetrachloride; enhanced green fluorescent protein; hydroxyproline; alanine aminotransferase; aspartate aminotransferase; carbon tetrachloride; hydroxyproline; serum albumin; alanine aminotransferase blood level; albumin blood level; amniotic fluid cell; amniotic fluid derive stem cell; animal experiment; animal model; animal tissue; article; aspartate aminotransferase blood level; content analysis; controlled study; germ layer; histopathology; in vivo study; liver fibrosis; liver function; male; mesentery; mouse; nonhuman; stem cell; stem cell transplantation; teratoma; tissue repair; transgenic mouse; amnion fluid; animal; blood; chemically induced; chemistry; cytology; disease model; fetal stem cell; Institute for Cancer Research mouse; liver; liver cirrhosis; metabolism; pathology; transplantation; Alanine Transaminase; Amniotic Fluid; Animals; Aspartate Aminotransferases; Carbon Tetrachloride; Disease Models, Animal; Fetal Stem Cells; Hydroxyproline; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred ICR; Serum Albumin
Type
journal article